COVID-19 and Dentistry: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Conner Chen and Version 1 by Sophie Jung.

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the cause of the current Coronavirus Disease 2019 (COVID-19) pandemic, whose first case was reported in December 2019 in Wuhan, Hubei province, China. In January 2021, the pandemic is still ongoing and is getting worse [1]. Dental surgery is considered to be a profession at high risk for being infected, and therefore transmitting SARS-CoV-2. Our professional practice was disrupted by lockdowns, resulting in reduced activity, new dental protocols and additional costs for staff protective equipment. This has caused unexpected financial difficulties for many dental practitioners. Even with treatments or vaccines, our professional practice will probably never revert back to the previous situation, as the new constraints may become permanent.

  • COVID-19
  • dentistry
  • SARS-CoV-2
Please wait, diff process is still running!

References

  1. Hanada, S.; Pirzadeh, M.; Carver, K.Y.; Deng, J.C. Respiratory Viral Infection-Induced Microbiome Alterations and Secondary Bacterial Pneumonia. Front. Immunol. 2018, 9, 2640.
  2. Yu, I.T.S.; Li, Y.; Wong, T.W.; Tam, W.; Chan, A.T.; Lee, J.H.W.; Leung, D.Y.C.; Ho, T. Evidence of Airborne Transmission of the Severe Acute Respiratory Syndrome Virus. N. Engl. J. Med. 2004, 350, 1731–1739.
  3. Xu, R.; Cui, B.; Duan, X.; Zhang, P.; Zhou, X.; Yuan, Q. Saliva: Potential Diagnostic Value and Transmission of 2019-NCoV. Int. J. Oral Sci. 2020, 12, 11.
  4. Zhang, W.; Du, R.-H.; Li, B.; Zheng, X.-S.; Yang, X.-L.; Hu, B.; Wang, Y.-Y.; Xiao, G.-F.; Yan, B.; Shi, Z.-L.; et al. Molecular and Serological Investigation of 2019-NCoV Infected Patients: Implication of Multiple Shedding Routes. Emerg. Microbes Infect. 2020, 9, 386–389.
  5. Wang, W.-K.; Chen, S.-Y.; Liu, I.-J.; Chen, Y.-C.; Chen, H.-L.; Yang, C.-F.; Chen, P.-J.; Yeh, S.-H.; Kao, C.-L.; Huang, L.-M.; et al. Detection of SARS-Associated Coronavirus in Throat Wash and Saliva in Early Diagnosis. Emerg. Infect. Dis. 2004, 10, 1213–1219.
  6. Laheij, A.M.G.A.; Kistler, J.O.; Belibasakis, G.N.; Välimaa, H.; de Soet, J.J.; European Oral Microbiology Workshop (EOMW) 2011. Healthcare-Associated Viral and Bacterial Infections in Dentistry. J. Oral Microbiol. 2012, 4.
  7. Adhikari, U.; Chabrelie, A.; Weir, M.; Boehnke, K.; McKenzie, E.; Ikner, L.; Wang, M.; Wang, Q.; Young, K.; Haas, C.N.; et al. A Case Study Evaluating the Risk of Infection from Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV) in a Hospital Setting Through Bioaerosols. Risk Anal. 2019, 39, 2608–2624.
  8. Herrera, D.; Serrano, J.; Roldán, S.; Sanz, M. Is the Oral Cavity Relevant in SARS-CoV-2 Pandemic? Clin. Oral Investig. 2020, 24, 2925–2930.
  9. Segal, L.N.; Clemente, J.C.; Tsay, J.-C.J.; Koralov, S.B.; Keller, B.C.; Wu, B.G.; Li, Y.; Shen, N.; Ghedin, E.; Morris, A.; et al. Enrichment of the Lung Microbiome with Oral Taxa Is Associated with Lung Inflammation of a Th17 Phenotype. Nat. Microbiol. 2016, 1, 16031.
  10. Hasan, A.; Paray, B.A.; Hussain, A.; Qadir, F.A.; Attar, F.; Aziz, F.M.; Sharifi, M.; Derakhshankhah, H.; Rasti, B.; Mehrabi, M.; et al. A Review on the Cleavage Priming of the Spike Protein on Coronavirus by Angiotensin-Converting Enzyme-2 and Furin. J. Biomol. Struct. Dyn. 2020, 1–9.
  11. Hamming, I.; Timens, W.; Bulthuis, M.L.C.; Lely, A.T.; Navis, G.J.; van Goor, H. Tissue Distribution of ACE2 Protein, the Functional Receptor for SARS Coronavirus. A First Step in Understanding SARS Pathogenesis. J. Pathol. 2004, 203, 631–637.
  12. Xu, H.; Zhong, L.; Deng, J.; Peng, J.; Dan, H.; Zeng, X.; Li, T.; Chen, Q. High Expression of ACE2 Receptor of 2019-NCoV on the Epithelial Cells of Oral Mucosa. Int. J. Oral Sci. 2020, 12, 8.
  13. Sakaguchi, W.; Kubota, N.; Shimizu, T.; Saruta, J.; Fuchida, S.; Kawata, A.; Yamamoto, Y.; Sugimoto, M.; Yakeishi, M.; Tsukinoki, K. Existence of SARS-CoV-2 Entry Molecules in the Oral Cavity. Int. J. Mol. Sci. 2020, 21, 6000.
  14. Liu, L.; Wei, Q.; Alvarez, X.; Wang, H.; Du, Y.; Zhu, H.; Jiang, H.; Zhou, J.; Lam, P.; Zhang, L.; et al. Epithelial Cells Lining Salivary Gland Ducts Are Early Target Cells of Severe Acute Respiratory Syndrome Coronavirus Infection in the Upper Respiratory Tracts of Rhesus Macaques. J. Virol. 2011, 85, 4025–4030.
  15. Xu, J.; Li, Y.; Gan, F.; Du, Y.; Yao, Y. Salivary Glands: Potential Reservoirs for COVID-19 Asymptomatic Infection. J. Dent. Res. 2020, 99, 989.
  16. Descamps, G.; Verset, L.; Trelcat, A.; Hopkins, C.; Lechien, J.R.; Journe, F.; Saussez, S. ACE2 Protein Landscape in the Head and Neck Region: The Conundrum of SARS-CoV-2 Infection. Biology 2020, 9, 235.
  17. Chen, L.; Zhao, J.; Peng, J.; Li, X.; Deng, X.; Geng, Z.; Shen, Z.; Guo, F.; Zhang, Q.; Jin, Y.; et al. Detection of SARS-CoV-2 in Saliva and Characterization of Oral Symptoms in COVID-19 Patients. Cell Prolif. 2020.
  18. Huang, N.; Perez, P.; Kato, T.; Mikami, Y.; Okuda, K.; Gilmore, R.C.; Conde, C.D.; Gasmi, B.; Stein, S.; Beach, M.; et al. Integrated Single-Cell Atlases Reveal an Oral SARS-CoV-2 Infection and Transmission Axis. MedRxiv 2020.
  19. López de Cicco, R.; Watson, J.C.; Bassi, D.E.; Litwin, S.; Klein-Szanto, A.J. Simultaneous Expression of Furin and Vascular Endothelial Growth Factor in Human Oral Tongue Squamous Cell Carcinoma Progression. Clin. Cancer Res. 2004, 10, 4480–4488.
  20. Böttcher, E.; Matrosovich, T.; Beyerle, M.; Klenk, H.-D.; Garten, W.; Matrosovich, M. Proteolytic Activation of Influenza Viruses by Serine Proteases TMPRSS2 and HAT from Human Airway Epithelium. J. Virol. 2006, 80, 9896–9898.
  21. Bertram, S.; Heurich, A.; Lavender, H.; Gierer, S.; Danisch, S.; Perin, P.; Lucas, J.M.; Nelson, P.S.; Pöhlmann, S.; Soilleux, E.J. Influenza and SARS-Coronavirus Activating Proteases TMPRSS2 and HAT Are Expressed at Multiple Sites in Human Respiratory and Gastrointestinal Tracts. PLoS ONE 2012, 7, e35876.
  22. Kielian, M. Enhancing Host Cell Infection by SARS-CoV-2. Science 2020, 370, 765–766.
  23. Varadarajan, S.; Balaji, T.M.; Sarode, S.C.; Sarode, G.S.; Sharma, N.K.; Gondivkar, S.; Gadbail, A.; Patil, S. EMMPRIN/BASIGIN as a Biological Modulator of Oral Cancer and COVID-19 Interaction: Novel Propositions. Med. Hypotheses 2020, 143, 110089.
  24. Shahrabi-Farahani, S.; Gallottini, M.; Martins, F.; Li, E.; Mudge, D.R.; Nakayama, H.; Hida, K.; Panigrahy, D.; D’Amore, P.A.; Bielenberg, D.R. Neuropilin 1 Receptor Is Up-Regulated in Dysplastic Epithelium and Oral Squamous Cell Carcinoma. Am. J. Pathol. 2016, 186, 1055–1064.
  25. Daly, J.L.; Simonetti, B.; Klein, K.; Chen, K.-E.; Williamson, M.K.; Antón-Plágaro, C.; Shoemark, D.K.; Simón-Gracia, L.; Bauer, M.; Hollandi, R.; et al. Neuropilin-1 Is a Host Factor for SARS-CoV-2 Infection. Science 2020, 370, 861–865.
  26. Cantuti-Castelvetri, L.; Ojha, R.; Pedro, L.D.; Djannatian, M.; Franz, J.; Kuivanen, S.; van der Meer, F.; Kallio, K.; Kaya, T.; Anastasina, M.; et al. Neuropilin-1 Facilitates SARS-CoV-2 Cell Entry and Infectivity. Science 2020, 370, 856–860.
  27. Wang, K.; Chen, W.; Zhou, Y.-S.; Lian, J.-Q.; Zhang, Z.; Du, P.; Gong, L.; Zhang, Y.; Cui, H.-Y.; Geng, J.-J.; et al. SARS-CoV-2 Invades Host Cells via a Novel Route: CD147-Spike Protein. BioRxiv 2020.
  28. Tu, Y.-P.; Jennings, R.; Hart, B.; Cangelosi, G.A.; Wood, R.C.; Wehber, K.; Verma, P.; Vojta, D.; Berke, E.M. Swabs Collected by Patients or Health Care Workers for SARS-CoV-2 Testing. N. Engl. J. Med. 2020, 383, 494–496.
  29. Pellegrino, R.; Cooper, K.W.; Di Pizio, A.; Joseph, P.V.; Bhutani, S.; Parma, V. Corona Viruses and the Chemical Senses: Past, Present, and Future. Chem. Senses 2020.
  30. Freni, F.; Meduri, A.; Gazia, F.; Nicastro, V.; Galletti, C.; Aragona, P.; Galletti, C.; Galletti, B.; Galletti, F. Symptomatology in Head and Neck District in Coronavirus Disease (COVID-19): A Possible Neuroinvasive Action of SARS-CoV-2. Am. J. Otolaryngol. 2020, 41, 102612.
  31. Capocasale, G.; Nocini, R.; Faccioni, P.; Donadello, D.; Bertossi, D.; Albanese, M.; Zotti, F. How to Deal with Coronavirus Disease 2019: A Comprehensive Narrative Review about Oral Involvement of the Disease. Clin. Exp. Dent. Res. 2020.
  32. Brandão, T.B.; Gueiros, L.A.; Melo, T.S.; Prado-Ribeiro, A.C.; Nesrallah, A.C.F.A.; Prado, G.V.B.; Santos-Silva, A.R.; Migliorati, C.A. Oral Lesions in Patients with SARS-CoV-2 Infection: Could the Oral Cavity Be a Target Organ? Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2020.
  33. Gupta, S.; Mohindra, R.; Chauhan, P.K.; Singla, V.; Goyal, K.; Sahni, V.; Gaur, R.; Verma, D.K.; Ghosh, A.; Soni, R.K.; et al. SARS-CoV-2 Detection in Gingival Crevicular Fluid. J. Dent. Res. 2020, 22034520970536.
  34. Badran, Z.; Gaudin, A.; Struillou, X.; Amador, G.; Soueidan, A. Periodontal Pockets: A Potential Reservoir for SARS-CoV-2? Med. Hypotheses 2020, 143, 109907.
  35. Fiorillo, L.; Cervino, G.; Laino, L.; D’Amico, C.; Mauceri, R.; Tozum, T.F.; Gaeta, M.; Cicciù, M. Porphyromonas Gingivalis, Periodontal and Systemic Implications: A Systematic Review. Dent. J. 2019, 7, 114.
  36. Li, X.; Li, C.; Liu, J.-C.; Pan, Y.-P.; Li, Y.-G. In Vitro Effect of Porphyromonas Gingivalis Combined with Influenza A Virus on Respiratory Epithelial Cells. Arch. Oral Biol. 2018, 95, 125–133.
  37. Kaczor-Urbanowicz, K.E.; Martin Carreras-Presas, C.; Aro, K.; Tu, M.; Garcia-Godoy, F.; Wong, D.T. Saliva Diagnostics—Current Views and Directions. Exp. Biol. Med. (Maywood) 2017, 242, 459–472.
  38. To, K.K.-W.; Tsang, O.T.-Y.; Leung, W.-S.; Tam, A.R.; Wu, T.-C.; Lung, D.C.; Yip, C.C.-Y.; Cai, J.-P.; Chan, J.M.-C.; Chik, T.S.-H.; et al. Temporal Profiles of Viral Load in Posterior Oropharyngeal Saliva Samples and Serum Antibody Responses during Infection by SARS-CoV-2: An Observational Cohort Study. Lancet Infect. Dis. 2020, 20, 565–574.
  39. Sabino-Silva, R.; Jardim, A.C.G.; Siqueira, W.L. Coronavirus COVID-19 Impacts to Dentistry and Potential Salivary Diagnosis. Clin. Oral Investig. 2020, 24, 1619–1621.
  40. Wölfel, R.; Corman, V.M.; Guggemos, W.; Seilmaier, M.; Zange, S.; Müller, M.A.; Niemeyer, D.; Jones, T.C.; Vollmar, P.; Rothe, C.; et al. Virological Assessment of Hospitalized Patients with COVID-2019. Nature 2020, 581, 465–469.
  41. Kim, S.E.; Lee, J.Y.; Lee, A.; Kim, S.; Park, K.H.; Jung, S.I.; Kang, S.J.; Oh, T.H.; Kim, U.J.; Lee, S.Y.; et al. Viral Load Kinetics of SARS-CoV-2 Infection in Saliva in Korean Patients: A Prospective Multi-Center Comparative Study. J. Korean Med. Sci. 2020, 35, e287.
  42. Wyllie, A.L.; Fournier, J.; Casanovas-Massana, A.; Campbell, M.; Tokuyama, M.; Vijayakumar, P.; Warren, J.L.; Geng, B.; Muenker, M.C.; Moore, A.J.; et al. Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2. N. Engl. J. Med. 2020, 383, 1283–1286.
  43. Zhu, J.; Guo, J.; Xu, Y.; Chen, X. Viral Dynamics of SARS-CoV-2 in Saliva from Infected Patients. J. Infect. 2020, 81, e48–e50.
  44. Azzi, L.; Baj, A.; Alberio, T.; Lualdi, M.; Veronesi, G.; Carcano, G.; Ageno, W.; Gambarini, C.; Maffioli, L.; Saverio, S.D.; et al. Rapid Salivary Test Suitable for a Mass Screening Program to Detect SARS-CoV-2: A Diagnostic Accuracy Study. J. Infect. 2020, 81, e75–e78.
  45. Han, M.S.; Seong, M.-W.; Kim, N.; Shin, S.; Cho, S.I.; Park, H.; Kim, T.S.; Park, S.S.; Choi, E.H. Viral RNA Load in Mildly Symptomatic and Asymptomatic Children with COVID-19, Seoul, South Korea. Emerg. Infect. Dis. 2020, 26, 2497–2499.
  46. To, K.K.-W.; Tsang, O.T.-Y.; Yip, C.C.-Y.; Chan, K.-H.; Wu, T.-C.; Chan, J.M.-C.; Leung, W.-S.; Chik, T.S.-H.; Choi, C.Y.-C.; Kandamby, D.H.; et al. Consistent Detection of 2019 Novel Coronavirus in Saliva. Clin. Infect. Dis. 2020, 71, 841–843.
  47. Iwasaki, S.; Fujisawa, S.; Nakakubo, S.; Kamada, K.; Yamashita, Y.; Fukumoto, T.; Sato, K.; Oguri, S.; Taki, K.; Senjo, H.; et al. Comparison of SARS-CoV-2 Detection in Nasopharyngeal Swab and Saliva. J. Infect. 2020, 81, e145–e147.
  48. Yoon, J.G.; Yoon, J.; Song, J.Y.; Yoon, S.Y.; Lim, C.S.; Seong, H.; Noh, J.Y.; Cheong, H.J.; Kim, W.J. Clinical Significance of a High SARS-CoV-2 Viral Load in the Saliva. J. Korean Med. Sci. 2020, 35, e195.
  49. Cheng, V.C.C.; Wong, S.-C.; Chen, J.H.K.; Yip, C.C.Y.; Chuang, V.W.M.; Tsang, O.T.Y.; Sridhar, S.; Chan, J.F.W.; Ho, P.-L.; Yuen, K.-Y. Escalating Infection Control Response to the Rapidly Evolving Epidemiology of the Coronavirus Disease 2019 (COVID-19) Due to SARS-CoV-2 in Hong Kong. Infect. Control Hosp. Epidemiol. 2020, 41, 493–498.
  50. Nagura-Ikeda, M.; Imai, K.; Tabata, S.; Miyoshi, K.; Murahara, N.; Mizuno, T.; Horiuchi, M.; Kato, K.; Imoto, Y.; Iwata, M.; et al. Clinical Evaluation of Self-Collected Saliva by Quantitative Reverse Transcription-PCR (RT-QPCR), Direct RT-QPCR, Reverse Transcription-Loop-Mediated Isothermal Amplification, and a Rapid Antigen Test to Diagnose COVID-19. J. Clin. Microbiol. 2020, 58.
  51. Williams, E.; Isles, N.; Chong, B.; Bond, K.; Yoga, Y.; Druce, J.; Catton, M.; Ballard, S.A.; Howden, B.P.; Williamson, D.A. Detection of SARS-CoV-2 in Saliva: Implications for Specimen Transport and Storage. J. Med. Microbiol. 2020.
  52. Walsh, K.A.; Jordan, K.; Clyne, B.; Rohde, D.; Drummond, L.; Byrne, P.; Ahern, S.; Carty, P.G.; O’Brien, K.K.; O’Murchu, E.; et al. SARS-CoV-2 Detection, Viral Load and Infectivity over the Course of an Infection. J. Infect. 2020, 81, 357–371.
  53. Tajima, Y.; Suda, Y.; Yano, K. A Case Report of SARS-CoV-2 Confirmed in Saliva Specimens up to 37 Days after Onset: Proposal of Saliva Specimens for COVID-19 Diagnosis and Virus Monitoring. J. Infect. Chemother. 2020, 26, 1086–1089.
  54. Azzi, L.; Carcano, G.; Gianfagna, F.; Grossi, P.; Gasperina, D.D.; Genoni, A.; Fasano, M.; Sessa, F.; Tettamanti, L.; Carinci, F.; et al. Saliva Is a Reliable Tool to Detect SARS-CoV-2. J. Infect. 2020, 81, e45–e50.
  55. Kojima, N.; Turner, F.; Slepnev, V.; Bacelar, A.; Deming, L.; Kodeboyina, S.; Klausner, J.D. Self-Collected Oral Fluid and Nasal Swab Specimens Demonstrate Comparable Sensitivity to Clinician-Collected Nasopharyngeal Swab Specimens for the Detection of SARS-CoV-2. Clin. Infect. Dis. 2020.
  56. Bosworth, A.; Whalley, C.; Poxon, C.; Wanigasooriya, K.; Pickles, O.; Aldera, E.L.; Papakonstantinou, D.; Morley, G.L.; Walker, E.M.; Zielinska, A.E.; et al. Rapid Implementation and Validation of a Cold-Chain Free SARS-CoV-2 Diagnostic Testing Workflow to Support Surge Capacity. J. Clin. Virol. 2020, 128, 104469.
  57. Yokota, I.; Shane, P.Y.; Okada, K.; Unoki, Y.; Yang, Y.; Inao, T.; Sakamaki, K.; Iwasaki, S.; Hayasaka, K.; Sugita, J.; et al. Mass Screening of Asymptomatic Persons for SARS-CoV-2 Using Saliva. Clin. Infect. Dis. 2020.
  58. Landry, M.L.; Criscuolo, J.; Peaper, D.R. Challenges in Use of Saliva for Detection of SARS CoV-2 RNA in Symptomatic Outpatients. J. Clin. Virol. 2020, 130, 104567.
  59. Azzi, L.; Carcano, G.; Dalla Gasperina, D.; Sessa, F.; Maurino, V.; Baj, A. Two Cases of COVID-19 with Positive Salivary and Negative Pharyngeal or Respiratory Swabs at Hospital Discharge: A Rising Concern. Oral Dis. 2020.
  60. Jeong, H.W.; Kim, S.-M.; Kim, H.-S.; Kim, Y.-I.; Kim, J.H.; Cho, J.Y.; Kim, S.; Kang, H.; Kim, S.-G.; Park, S.-J.; et al. Viable SARS-CoV-2 in Various Specimens from COVID-19 Patients. Clin. Microbiol. Infect. 2020, 26, 1520–1524.
  61. Sohn, Y.; Jeong, S.J.; Chung, W.S.; Hyun, J.H.; Baek, Y.J.; Cho, Y.; Kim, J.H.; Ahn, J.Y.; Choi, J.Y.; Yeom, J.-S. Assessing Viral Shedding and Infectivity of Asymptomatic or Mildly Symptomatic Patients with COVID-19 in a Later Phase. J. Clin. Med. 2020, 9, 2924.
  62. Papineni, R.S.; Rosenthal, F.S. The Size Distribution of Droplets in the Exhaled Breath of Healthy Human Subjects. J. Aerosol Med. 1997, 10, 105–116.
  63. Abkarian, M.; Mendez, S.; Xue, N.; Yang, F.; Stone, H.A. Speech Can Produce Jet-like Transport Relevant to Asymptomatic Spreading of Virus. Proc. Natl. Acad. Sci. USA 2020, 117, 25237–25245.
  64. Fahy, J.V.; Dickey, B.F. Airway Mucus Function and Dysfunction. N. Engl. J. Med. 2010, 363, 2233–2247.
  65. Xie, X.; Li, Y.; Chwang, A.T.Y.; Ho, P.L.; Seto, W.H. How Far Droplets Can Move in Indoor Environments—Revisiting the Wells Evaporation-Falling Curve. Indoor Air 2007, 17, 211–225.
  66. Zhang, R.; Li, Y.; Zhang, A.L.; Wang, Y.; Molina, M.J. Identifying Airborne Transmission as the Dominant Route for the Spread of COVID-19. Proc. Natl. Acad. Sci. USA 2020, 117, 14857–14863.
  67. Seminara, G.; Carli, B.; Forni, G.; Fuzzi, S.; Mazzino, A.; Rinaldo, A. Biological Fluid Dynamics of Airborne COVID-19 Infection. Rend. Lincei Sci. Fis. Nat. 2020, 1–33.
  68. Kampf, G.; Todt, D.; Pfaender, S.; Steinmann, E. Persistence of Coronaviruses on Inanimate Surfaces and Their Inactivation with Biocidal Agents. J. Hosp. Infect. 2020, 104, 246–251.
  69. Van Doremalen, N.; Bushmaker, T.; Morris, D.H.; Holbrook, M.G.; Gamble, A.; Williamson, B.N.; Tamin, A.; Harcourt, J.L.; Thornburg, N.J.; Gerber, S.I.; et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. N. Engl. J. Med. 2020, 382, 1564–1567.
  70. Chin, A.W.H.; Chu, J.T.S.; Perera, M.R.A.; Hui, K.P.Y.; Yen, H.-L.; Chan, M.C.W.; Peiris, M.; Poon, L.L.M. Stability of SARS-CoV-2 in Different Environmental Conditions. Lancet Microbe 2020, 1, e10.
  71. Santarpia, J.L.; Rivera, D.N.; Herrera, V.L.; Morwitzer, M.J.; Creager, H.M.; Santarpia, G.W.; Crown, K.K.; Brett-Major, D.M.; Schnaubelt, E.R.; Broadhurst, M.J.; et al. Aerosol and Surface Contamination of SARS-CoV-2 Observed in Quarantine and Isolation Care. Sci. Rep. 2020, 10, 12732.
  72. World Health Organization. Transmission of SARS-CoV-2: Implications for Infection Prevention Precautions: Scientific Brief., 9 July 2020; WHO: Geneva, Switzerland, 2020.
  73. World Health Organization Diagnostic Testing for SARS-CoV-2: Interim Guidance, 11 September 2020. Available online: (accessed on 8 November 2020).
  74. European Centre for Disease Prevention and Control. COVID-19 Infection Prevention and Control. Measures for Primary Care, Including General Practitioner Practices, Dental Clinics and Pharmacy Settings: First Update—19 October 2020; ECDC: Stockholm, Sweden, 2020.
  75. Centers for Disease Control and Prevention. Interim Infection Prevention and Control Guidance for Dental Settings during the Coronavirus Disease 2019 (COVID-19) Pandemic—28 August 2020. Available online: (accessed on 23 November 2020).
  76. World Health Organization. Infection Prevention and Control during Health Care When Coronavirus Disease (COVID-19) Is Suspected or Confirmed: Interim Guidance, 29 June 2020; WHO: Geneva, Switzerland, 2020.
  77. Centers for Disease Control and Prevention. Infection Control Guidance—4 November 2020. Available online: (accessed on 8 November 2020).
  78. World Health Organization. Prevention, Identification and Management of Health Worker Infection in the Context of COVID-19: Interim Guidance, 30 October 2020; WHO: Geneva, Switzerland, 2020.
  79. Centers for Disease Control and Prevention Testing Healthcare Personnel—17 July 2020. Available online: (accessed on 23 November 2020).
  80. European Centre for Disease Prevention and Control. Infection Prevention and Control and Preparedness for COVID-19 in Healthcare Settings—Fifth Update—6 October 2020; ECDC: Stockholm, Sweden, 2020.
  81. Centers for Disease Control and Prevention Return-to-Work Criteria—10 August 2020. Available online: (accessed on 23 November 2020).
  82. World Health Organization. Standard Precautions in Health Care; WHO: Geneva, Switzerland, 2007.
  83. World Health Organization. Hand Hygiene: Why, How & When? WHO: Geneva, Switzerland, 2009.
  84. World Health Organization. WHO Guidelines on Hand Hygiene in Health Care; WHO: Geneva, Switzerland, 2009.
  85. World Health Organization. Water, Sanitation, Hygiene, and Waste Management for SARS-CoV-2, the Virus That Causes COVID-19: Interim Guidance, 29 July 2020; WHO: Geneva, Switzerland, 2020.
  86. World Health Organization. Infection Prevention and Control of Epidemic—And Pandemic—Prone Acute Respiratory Infections in Health Care: WHO Guidelines; WHO: Geneva, Switzerland, 2014.
  87. World Health Organization. Rational Use of Personal Protective Equipment for Coronavirus Disease (COVID-19) and Considerations during Severe Shortages: Interim Guidance, 6 April 2020; WHO: Geneva, Switzerland, 2020.
  88. World Health Organization. Rational Use of Personal Protective Equipment (PPE) for Coronavirus Disease (COVID-19): Interim Guidance, 19 March 2020; WHO: Geneva, Switzerland, 2020.
  89. World Health Organization. Advice on the Use of Masks in the Context of COVID-19: Interim Guidance, 5 June 2020; WHO: Geneva, Switzerland, 2020.
  90. World Health Organization. Criteria for Releasing COVID-19 Patients from Isolation: Scientific Brief., 17 June 2020; WHO: Geneva, Switzerland, 2020.
  91. European Centre for Disease Prevention and Control. Guidance for Discharge and Ending of Isolation of People with COVID-19—16 October 2020; ECDC: Stockholm, Sweden, 2020.
  92. Centers for Disease Control and Prevention. Ending Home Isolation: Interim Guidance, 20 July 2020. Available online: (accessed on 23 November 2020).
  93. European Centre for Disease Prevention and Control. Use of Gloves in Healthcare and Non-Healthcare Settings in the Context of the COVID 19 Pandemic—2 July 2020; ECDC: Stockholm, Sweden, 2020.
  94. European Centre for Disease Prevention and Control. Guidance for Wearing and Removing Personal Protective Equipment in Healthcare Settings for the Care of Patients with Suspected or Confirmed COVID-19—February 2020; ECDC: Stockholm, Sweden, 2020.
  95. European Centre for Disease Prevention and Control. Risk Related to Spread of New SARS-CoV-2 Variants of Concern in the EU/EEA—First Update—21 January 2021; ECDC: Stockholm, Sweden, 2021.
  96. Centers for Disease Control and Prevention. COVID-19 and Your Health—Your Guide to Masks—January 2021. Available online: (accessed on 21 January 2021).
  97. World Health Organization. Mask Use in the Context of COVID-19: Interim Guidance; WHO: Geneva, Switzerland, 2020.
  98. World Health Organization. Cleaning and Disinfection of Environmental Surfaces in the Context of COVID-19: Interim Guidance, 15 May 2020; WHO: Geneva, Switzerland, 2020.
  99. European Centre for Disease Prevention and Control. Disinfection of Environments in Healthcare and Non-Healthcare Settings Potentially Contaminated with SARS-CoV-2—March 2020; ECDC: Stockholm, Sweden, 2020.
  100. World Health Organization. Natural Ventilation for Infection Control in Health Care Settings; WHO: Geneva, Switzerland, 2009.
  101. European Centre for Disease Prevention and Control. Heating, Ventilation and Air-Conditioning Systems in the Context of COVID-19: First Update—10 November 2020; ECDC: Stockholm, Sweden, 2020.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
ScholarVision Creations
Feedback